Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …

Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant
improvement in invasive disease-free survival and distant relapse-free survival in hormone …

Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …

BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Purpose: Estrogen receptor (ER) alpha signaling is a known driver of ER-positive
(ER+)/human epidermal growth factor receptor 2 negative (HER2−) breast cancer …

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as
monotherapy and in combination with fulvestrant in women with hormone receptor (HR) …

At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor
(AI) significantly improved progression-free survival (PFS) and objective response rate …

Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been
approved for the treatment of hormone receptor-positive breast cancer. In this study, we use …

For the past two decades, cellular senescence has been recognized as a central component
of the tumor cell response to chemotherapy and radiation. Traditionally, this form of …